ArticlePLoS pathogens2014
A novel mouse model of Campylobacter jejuni gastroenteritis reveals key pro-inflammatory and tissue protective roles for Toll-like receptor signaling during infection.
Article in PLoS pathogens, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 73 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
73 citing papers in PubMed.
- Differential antibiosis predisposes mice to Campylobacter jejuni infection: Deeper insights into the impact of the gut microbiota composition in colonization resistance.European journal of microbiology & immunology · 2025Article
- Novel M23 peptidases Pgp4, Pgp5, and Pgp6 contribute to helical cell shape inFrontiers in microbiology · 2025Article
- Therapeutic and protective approaches to combatFrontiers in pharmacology · 2025Review
- Review
- Navigating ESKAPE Pathogens: Considerations and Caveats for Animal Infection Models Development.ACS infectious diseases · 2024Review
- Antibiotic-induced microbiome depletion promotes intestinal colonization by Campylobacter jejuni in mice.BMC microbiology · 2024Article
- Gut metabolite L-lactate supportsProceedings of the National Academy of Sciences of the United States of America · 2024Article
- QcrC is a potential target for antibody therapy and vaccination to controlFrontiers in microbiology · 2024Article
- Animal and In Vitro Models as Powerful Tools to Decipher the Effects of Enteric Pathogens on the Human Gut Microbiota.Microorganisms · 2023Review
- Polysaccharide fromNutrients · 2023Article
- A Systematic Review on the Role of Wildlife as Carriers and Spreaders ofAnimals : an open access journal from MDPI · 2023Review
- Molecular Targets inBiomolecules · 2023Review
- Metabolomic signatures of intestinal colonization resistance againstFrontiers in microbiology · 2023Article
- Effect of treatment withFrontiers in microbiology · 2023Article
- Combined treatment with Rg1 and adipose-derived stem cells alleviates DSS-induced colitis in a mouse model.Stem cell research & therapy · 2022Article
- Structure-based inhibitor design for reshaping bacterial morphology.Communications biology · 2022Article
- Aspartate α-decarboxylase a new therapeutic target in the fight againstFrontiers in microbiology · 2022Article
- The Distribution ofGenes · 2021Article
- Fasting increases microbiome-based colonization resistance and reduces host inflammatory responses during an enteric bacterial infection.PLoS pathogens · 2021Article
- The Host Cellular Immune Response to Infection by Campylobacter Spp. and Its Role in Disease.Infection and immunity · 2021Review
13 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Campylobacter jejuni is a major source of foodborne illness in the developed world, and a common cause of clinical gastroenteritis. Exactly how C. jejuni colonizes its host's intestines and causes disease is poorly understood. Although it causes severe diarrhea and gastroenteritis in humans, C. jejuni typically dwells as a commensal microbe within the intestines of most animals, including birds, where its colonization is asymptomatic. Pretreatment of C57BL/6 mice with the antibiotic vancomycin facilitated intestinal C. jejuni colonization, albeit with minimal pathology. In contrast, vancomycin pretreatment of mice deficient in SIGIRR (Sigirr(-/-)), a negative regulator of MyD88-dependent signaling led to heavy and widespread C. jejuni colonization, accompanied by severe gastroenteritis involving strongly elevated transcription of Th1/Th17 cytokines. C. jejuni heavily colonized the cecal and colonic crypts of Sigirr(-/-) mice, adhering to, as well as invading intestinal epithelial cells. This infectivity was dependent on established C. jejuni pathogenicity factors, capsular polysaccharides (kpsM) and motility/flagella (flaA). We also explored the basis for the inflammatory response elicited by C. jejuni in Sigirr(-/-) mice, focusing on the roles played by Toll-like receptors (TLR) 2 and 4, as these innate receptors were strongly stimulated by C. jejuni. Despite heavy colonization, Tlr4(-/-)/Sigirr(-/-) mice were largely unresponsive to infection by C. jejuni, whereas Tlr2(-/-)/Sigirr(-/-) mice developed exaggerated inflammation and pathology. This indicates that TLR4 signaling underlies the majority of the enteritis seen in this model, whereas TLR2 signaling had a protective role, acting to promote mucosal integrity. Furthermore, we found that loss of the C. jejuni capsule led to increased TLR4 activation and exaggerated inflammation and gastroenteritis. Together, these results validate the use of Sigirr(-/-) mice as an exciting and relevant animal model for studying the pathogenesis and innate immune responses to C. jejuni.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.